This inventor holds 3 USPTO granted patents. Top assignees: The Salk Institute, Scripps Research Institute, Icahn School of Medicine at Mount Sinai. Active years: 2011-2016.
Company Filing History:
3 out of 593 
2 out of 1,205 
1 out of 535 
Years Active: 2011-2016
Title: John Young: Innovator in Antiviral Research
Introduction
John Young is a prominent inventor based in San Diego, CA (US). He has made significant contributions to the field of antiviral research, holding a total of 3 patents. His work focuses on developing innovative methods and compositions to combat viral infections, particularly influenza.
Latest Patents
One of John Young's latest patents is titled "Compositions and methods for inhibiting human host factors required for influenza virus replication." This application addresses the modulation of host cell factors essential for influenza virus replication. It involves compounds, including nucleic acid compounds such as small interfering RNAs (siRNAs) and small molecules, that target human host cell factors involved in the replication process. The application also outlines methods for treating influenza virus infections and associated symptoms through the administration of these compounds.
Another notable patent is the "Antitoxin and vaccine platform based on nodavirus VLPs." This patent provides compositions for antitoxins and vaccines based on virus-like particles (VLPs) derived from nodavirus. It includes anthrax antitoxin and vaccine compositions, as well as methods for treating toxins with VLP-based antitoxins. Additionally, it describes methods for eliciting an immune response using immunogen-decorated VLPs.
Career Highlights
John Young has worked at prestigious research institutions, including The Salk Institute and The Scripps Research Institute. His experience in these organizations has allowed him to collaborate with leading scientists and contribute to groundbreaking research in the field of virology.
Collaborations
Throughout his career, John has collaborated with notable colleagues such as Anette Schneemann and Marianne Manchester. These partnerships have further enhanced his research and innovation in antiviral therapies.
Conclusion
John Young is a dedicated inventor whose work in antiviral research has the potential to significantly impact public health. His innovative patents and collaborations reflect his commitment to advancing scientific knowledge and developing effective treatments for viral infections.